May 9, 2024 02:48 PM EDT
R&D
Cell/Gene Tx

Across two clin­i­cal tri­als, gene ther­a­py re­stores hear­ing in chil­dren deaf since birth: #AS­GCT24

Lei Lei Wu

News Reporter

BAL­TI­MORE — Ten out of 11 chil­dren who were born deaf can now hear af­ter re­ceiv­ing a gene ther­a­py from a Shang­hai biotech, ac­cord­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times